Novocure (NASDAQ: NVCR) announced today that management will participate in the 44 th Annual J.P. Morgan Healthcare Conference taking place in San Francisco on January 12-15, 2026. Frank...
Novocure (NASDAQ: NVCR) today announced the appointment of Frank Leonard as Chief Executive Officer (CEO), effective immediately. Mr. Leonard previously served as President of Novocure and succeeds Ashley...
Novocure (NASDAQ: NVCR) announced today that management will participate in the 37 th Annual Piper Sandler Healthcare Conference in New York on Tuesday, December 2, 2025. William Doyle,...
Novocure (NASDAQ: NVCR) announced today that management will participate in the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025. Ashley Cordova, Chief Executive Officer,...
Quarterly net revenues of $167 million, up 8% year-over-year, with 4,416 active patients on therapy as of September 30, 2025 Premarket approval application for Tumor...
Novocure (NASDAQ: NVCR) announced today that it will present data at two upcoming oncology congresses, the 2025 European Association of Neuro-Oncology (EANO) Meeting, being held October 16-19 in Prague,...
Wedbush analyst David Nierengarten maintained a Hold rating on NovoCure today and set a price target of $18.00. The company’s shares closed last Friday at $13.49.Elevate Your Investing Strategy: Take...
Evercore ISI analyst Vijay Kumar maintained a Buy rating on NovoCure today and set a price target of $25.00. The company’s shares opened today at $14.50.Elevate Your Investing Strategy: Take advantage...
Novocure (NASDAQ: NVCR) will report financial results for the third quarter 2025 on October 30, 2025, before the U.S. financial markets open. Novocure management will host a conference call and...